explore -WSS

explore

author：focus 2025-09-07 17:27:41 - browse：2653

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Wearables generate powerful data but its not useful to doctors, yet

WSS

Case highlights the risks of experimental stem cell therapy

Big Tobacco's 'harm reduction': Is it for real, or a sham?

First medicine developed to treat MASH expected to be approved soon

Second House panel advances two

Air quality improving but still lags in Black, Hispanic communities

It's time to retire 'poor historian' from clinicians' vocabularies

hotspot

explore

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Data integrity in scientific journals requires "effort" by publishers, institutions

At least 13 dead in Texas as scorching temps continue

First medicine developed to treat MASH expected to be approved soon

Continuity nursing helped my family in our darkest PICU moments

Helping hospitals and community health centers plan for resilience

Alkermes shareholders re

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

RSV shot was 90% effective at preventing hospitalizations in kids

entertainment

Wearables generate powerful data but its not useful to doctors, yet

Sen. Paul opposes bill to ban Chinese biotechs

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Change Healthcare payments predicted restored March 15

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

explore

leisure time

focus

hotspot